Rituximab and ▼abatacept for rheumatoid arthritis
-
Relevant BNF section: 10.1.3
Abstract
Estimates from the UK indicate that around 0.5–1.0% of the population have rheumatoid arthritis.1 Here we assess the place of rituximab (MabThera – Roche Products Ltd) and ▼abatacept (Orencia – Bristol-Myers-Squibb), drugs in two new classes, which are licensed for certain adults with the condition.
